Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Illumina (ILMN) through the VizualStocks API.
Core Illumina revenue attributed to Asia-Pacific, excluding Greater China and the Middle East under its commercial-region reporting structure introduced in 2026. Comparatives beginning in 2024 are issuer-recast and include intersegment revenue before GRAIL’s spin-off.
apacRevenueValue of Illumina orders believed to be firm at fiscal year-end, including orders scheduled for shipment in later years. Customers may substitute products as new products are launched; this is an order balance rather than revenue recognized during the year.
backlogCore Illumina revenue attributed to Europe, the Middle East, Africa and Latin America under its commercial-region reporting structure introduced in 2026. Comparatives beginning in 2024 are issuer-recast and include intersegment revenue before GRAIL’s spin-off.
emealaRevenueCore Illumina revenue attributed to China, Taiwan and Hong Kong under its commercial-region reporting structure introduced in 2026. Comparatives beginning in 2024 are issuer-recast and include intersegment revenue before GRAIL’s spin-off.
greaterChinaRevenueRevenue from consumables for Illumina microarray assays used to measure genetic variation and related biological features. This product line is separate from sequencing consumables and excludes microarray instruments and services.
microarrayConsumablesRevenueRevenue from sales of Illumina instruments used to process and read microarray assays. It excludes microarray consumables and the associated services and other revenue.
microarrayInstrumentsRevenueRevenue from Illumina microarray services and associated development, licensing and other agreements. It excludes sales of microarray instruments and consumables.
microarrayServiceAndOtherRevenueRevenue from consumables used on Illumina sequencing platforms, including reagents and flow cells used to read genetic material. This is Core Illumina revenue, including sales to GRAIL before its June 2024 spin-off, before intersegment eliminations.
sequencingConsumablesRevenueRevenue from sales of Illumina DNA sequencing instruments, including its high-, mid- and low-throughput platforms. Consumables used with those instruments and instrument service contracts are reported separately.
sequencingInstrumentsRevenueCore Illumina revenue from sequencing services, sequencing instrument service contracts, and associated development, licensing and other agreements. It excludes GRAIL cancer-detection testing revenue during the period when GRAIL was consolidated.
sequencingServiceAndOtherRevenueCore Illumina revenue attributed to United States and Canada under its commercial-region reporting structure introduced in 2026. Comparatives beginning in 2024 are issuer-recast and include intersegment revenue before GRAIL’s spin-off.
uscanRevenueRevenue of the GRAIL reportable segment from cancer-detection testing and related activities while owned by Illumina. History starts with the August 18, 2021 acquisition and ends with the June 24, 2024 spin-off, so the first and last fiscal years include only the ownership period.
grailSegmentRevenueRevenue of Core Illumina during the period when Illumina reported Core Illumina and GRAIL as separate segments, including intersegment sales before consolidation eliminations. This historical segment series ends with the 2024 GRAIL spin-off; the product and regional series continue thereafter.
historicalCoreIlluminaSegmentRevenue